Kentucky Clinical Trials Report — May 2026

For Kentuckians considering participation in clinical research, May 2026 brings a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 70 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 13 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, wound healing, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Ovarian cancer
• Stage IV lung cancer AJCC V8
• Wounds and injuries
• Advance directives
• Alcohol risk behaviors
• Anaplastic astrocytoma
• Advanced NSCLC
• Anatomic stage III breast cancer AJCC V8
• Ankle sprains
• Appendicitis

Major Research Initiatives Launch in Kentucky

This month brings two significant new trials to Kentucky, both from a major pharmaceutical company and focusing on prevalent health challenges. These Phase 3 drug trials offer participants the chance to engage with cutting-edge treatments for obesity, heart failure, and type 2 diabetes.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight. The study seeks to understand how this new compound compares to a placebo in managing these complex conditions.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes. Participants will receive either CagriSema at one of two doses or Semaglutide, allowing researchers to compare the efficacy of these treatments.

Kentucky's Evolving Research Landscape

This month, Kentucky saw the opening of only 2 new clinical trials, a notable decrease compared to the 12 trials that launched in March 2026, and significantly lower than the 27 new trials seen in December 2025. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 986 clinical trials currently recruiting across 55 cities and 562 research sites.

The new research initiatives this month are concentrated in key urban areas, with sites for these studies available in Lexington, Louisville, and Owensboro. Specifically, new trial sites opened in:

• Lexington
• Louisville
• Owensboro

This distribution ensures that residents in different parts of the state have access to these important new studies, even as the overall number of new trials has decreased. The new studies are exclusively drug trials, reflecting a focus on pharmaceutical interventions for the conditions being investigated.

Participation Pathways: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 2 new trials launched this month, both include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials this month are specifically for children, or exclusively for females or males.

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research across Kentucky. While neither of the new trials this month is actively seeking healthy volunteers, a total of 79 clinical trials statewide are currently recruiting healthy participants. These studies play a vital role in understanding baseline health, testing new diagnostic tools, and evaluating the safety of potential treatments before they are introduced to patient populations. Interested individuals should explore these options to support medical advancements.

Industry sponsors continue to drive significant research efforts in Kentucky, with Novo Nordisk A/S sponsoring both of the new trials this month. Their focus on large-scale Phase 3 studies highlights a commitment to developing treatments for widespread conditions like obesity, heart failure, and type 2 diabetes.

As we move through May, the focus will likely remain on the ongoing enrollment in these significant Phase 3 trials, while the broader research community in Kentucky prepares for future waves of innovative studies to address a broad spectrum of health challenges across the state.